GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback